ABSTRACT
Acute graft-versus-host disease (aGvHD) is a frequent complication after allogeneic bone marrow/stem cell transplantation (BMT/SCT) induced by co-transplanted alloreactive conventional donor T cells. We previously demonstrated that the adoptive transfer of donor CD4+CD25+Foxp3+ regulatory T cells (Treg) at the time of BMT prevents aGvHD in murine models. Yet, the therapeutic potential of donor Treg for the treatment of established aGvHD has not yet been studied in detail. We now used in vitro expanded phenotypically and functionally stable murine Treg to explore their therapeutic efficacy in haploidentical aGvHD models. Upon transfer donor Treg ameliorate clinical and histologic signs of aGvHD and significantly improve survival. They migrate to lymphoid as well as aGvHD target organs, predominantly the gastrointestinal tract, where they inhibit the proliferation of conventional T cells, reduce the influx of myeloid cells, and the accumulation of inflammatory cytokines. Successfully treated animals restore aGvHD-induced tissue damage in target organs and lymphoid tissues, thereby supporting lymphocyte reconstitution. The therapeutically applied Treg population survives long term without conversion into pathogenic effector T cells. These results demonstrate that donor Treg not only prevent aGvHD, but are also efficacious for the treatment of this life-threatening BMT complication.
Subject(s)
Graft vs Host Disease/therapy , T-Lymphocytes, Regulatory/immunology , Animals , Bone Marrow Cells/cytology , Bone Marrow Transplantation/adverse effects , Cells, Cultured , Disease Models, Animal , Female , Immune System , Inflammation , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Myeloid Cells/pathology , Phenotype , Transplantation, Homologous/adverse effectsSubject(s)
Cell Separation/methods , DNA/isolation & purification , Epigenesis, Genetic , Flow Cytometry/methods , Forkhead Transcription Factors/metabolism , T-Lymphocyte Subsets/chemistry , T-Lymphocytes, Regulatory/chemistry , Binding Sites , Cell Lineage , CpG Islands , DNA/genetics , DNA/metabolism , DNA Methylation , Genome, Human , Humans , Molecular Weight , Protein Binding , Specimen Handling , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Staining and Labeling , T-Lymphocyte Subsets/metabolism , T-Lymphocytes, Regulatory/metabolism , Tissue FixationABSTRACT
DNA methylation participates in establishing and maintaining chromatin structures and regulates gene transcription during mammalian development and cellular differentiation. With few exceptions, research thus far has focused on gene promoters, and little is known about the extent, functional relevance, and regulation of cell type-specific DNA methylation at promoter-distal sites. Here, we present a comprehensive analysis of differential DNA methylation in human conventional CD4(+) T cells (Tconv) and CD4(+)CD25(+) regulatory T cells (Treg), cell types whose differentiation and function are known to be controlled by epigenetic mechanisms. Using a novel approach that is based on the separation of a genome into methylated and unmethylated fractions, we examined the extent of lineage-specific DNA methylation across whole gene loci. More than 100 differentially methylated regions (DMRs) were identified that are present mainly in cell type-specific genes (e.g., FOXP3, IL2RA, CTLA4, CD40LG, and IFNG) and show differential patterns of histone H3 lysine 4 methylation. Interestingly, the majority of DMRs were located at promoter-distal sites, and many of these areas harbor DNA methylation-dependent enhancer activity in reporter gene assays. Thus, our study provides a comprehensive, locus-wide analysis of lineage-specific methylation patterns in Treg and Tconv cells, links cell type-specific DNA methylation with histone methylation and regulatory function, and identifies a number of cell type-specific, CpG methylation-sensitive enhancers in immunologically relevant genes.
Subject(s)
CpG Islands/genetics , DNA Methylation , Enhancer Elements, Genetic/genetics , Histones/genetics , T-Lymphocytes/physiology , Cell Lineage , Chromatin/metabolism , Chromatin Immunoprecipitation , Epigenesis, Genetic , Gene Expression Profiling , Humans , Immunoprecipitation , Oligonucleotide Array Sequence Analysis , Polymerase Chain Reaction , Promoter Regions, Genetic , Spectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationABSTRACT
The adoptive transfer of CD4(+)CD25(+) natural regulatory T cells (Treg) is a promising strategy for the treatment of autoimmune diseases and the prevention of alloresponses after transplantation. Clinical trials exploring this strategy require efficient in vitro expansion of this rare cell population. Protocols developed thus far rely on high-grade purification of Treg prior to culture initiation, a process still hampered by the lack of Treg cell-specific surface markers. Depletion of CD127(+) cells was shown to separate activated conventional T cells from natural Treg cell populations allowing the isolation of highly enriched FOXP3(+) cells with all functional and molecular characteristics of natural Treg. Here, we demonstrate that upon in vitro expansion, CpG methylation in a conserved region within the FOXP3 gene locus increased in CD4(+)CD25(+)CD127(low) Treg, correlating with loss of FOXP3 expression and emergence of pro-inflammatory cytokines. Further analysis identified CD45RA(-)FOXP3(+) memory-type Treg as the main source of converting cells, whereas CD45RA(+)FOXP3(+) Treg from the same donors showed no conversion within 3 wk of in vitro expansion. Thus, Treg cell lineage differentiation does not seem to represent a final fate decision, as natural Treg can lose their cell-type-specific characteristics after repetitive TCR stimulation.
Subject(s)
Epigenesis, Genetic , Forkhead Transcription Factors/genetics , Lymphocyte Activation , T-Lymphocyte Subsets/immunology , T-Lymphocytes, Regulatory/immunology , Antibodies/pharmacology , CD28 Antigens/immunology , CD3 Complex/immunology , CD4 Antigens/immunology , Cells, Cultured , CpG Islands , DNA Methylation , Humans , Interleukin-2/pharmacology , Interleukin-2 Receptor alpha Subunit/immunology , Lymphocyte Activation/genetics , T-Lymphocyte Subsets/metabolism , T-Lymphocytes, Regulatory/drug effectsABSTRACT
The transcription factor FOXP3 is critical for development and function of regulatory T cells (Treg). Their number and functioning appears to be crucial in the prevention of autoimmunity and allergy, but also to be a negative prognostic marker for various solid tumors. Although expression of the transcription factor FOXP3 currently constitutes the best-known marker for Treg, in humans, transient expression is also observed in activated non-Treg. Extending our recent findings for the murine foxp3 locus, we observed epigenetic modification of several regions in the human FOXP3 locus exclusively occurring in Treg. Importantly, activated conventional CD4(+) T cells and TGF-beta-treated cells displayed no FOXP3 DNA demethylation despite expression of FOXP3, whereas subsets of Treg stable even upon extended in vitro expansion remained demethylated. To investigate whether a whole set of genes might be epigenetically imprinted in the Treg lineage, we conducted a genome-wide differential methylation hybridization analysis. Several genes were found displaying differential methylation between Treg and conventional T cells, but none beside FOXP3 turned out to be entirely specific to Treg when tested on a broad panel of cells and tissues. We conclude that FOXP3 DNA demethylation constitutes the most reliable criterion for natural Treg available at present.
Subject(s)
Forkhead Transcription Factors/genetics , Forkhead Transcription Factors/metabolism , Lymphocyte Activation/immunology , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Calcium-Binding Proteins/genetics , Calcium-Binding Proteins/metabolism , Cell Proliferation , Cells, Cultured , DNA Methylation , Female , Gene Expression Profiling , Genetic Markers , Humans , Immunity, Innate/immunology , Interleukin-2 Receptor alpha Subunit/metabolism , Male , Sensitivity and Specificity , T-Lymphocytes/cytology , T-Lymphocytes/drug effects , Trans-Activators/genetics , Trans-Activators/metabolism , Transforming Growth Factor beta/pharmacologyABSTRACT
Thymus-derived CD4+ CD25+ regulatory T cells suppress autoreactive CD4+ and CD8+ T cells and thereby protect from autoimmunity. In animal models, adoptive transfer of CD4+ CD25+ regulatory T cells has been shown to prevent and even cure autoimmune diseases as well as pathogenic alloresponses after solid organ and stem-cell transplantations. We recently described methods for the efficient in vitro expansion of human regulatory T cells for clinical applications. We now demonstrate that only CCR7- and L-selectin (CD62L)-coexpressing cells within expanded CD4+ CD25high T cells maintain phenotypic and functional characteristics of regulatory T cells. Further analysis revealed that these cells originate from CD45RA+ naive cells within the CD4+ CD25high T-cell compartment, as only this subpopulation homogeneously expressed CD62L, CCR7, cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), and forkhead box P3 (FOXP3), produced no inflammatory cytokines and maintained robust suppressive activity after expansion. In contrast, cell lines derived from CD45RA- memory-type CD4+ CD25high T cells lost expression of lymph node homing receptors CCR7 and CD62L, contained interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) as well as IL-10-secreting cells, showed only moderate suppression and, most importantly, did not maintain FOXP3 expression. Based on these unexpected findings, we suggest that isolation and expansion of CD45RA+ naive CD4+ CD25high T cells is the best strategy for adoptive regulatory T (Treg)-cell therapies.
Subject(s)
Cell Differentiation/immunology , Cell Proliferation , Gene Expression Regulation/immunology , Leukocyte Common Antigens/immunology , T-Lymphocytes, Regulatory/immunology , Thymus Gland/immunology , Antigens, CD/biosynthesis , Antigens, CD/immunology , Antigens, Differentiation/biosynthesis , Antigens, Differentiation/immunology , CTLA-4 Antigen , Cells, Cultured , Cytokines/biosynthesis , Cytokines/immunology , Female , Forkhead Transcription Factors/biosynthesis , Forkhead Transcription Factors/immunology , Humans , Immunotherapy, Adoptive , L-Selectin/biosynthesis , L-Selectin/immunology , Leukocyte Common Antigens/biosynthesis , Male , Receptors, CCR7 , Receptors, Chemokine/biosynthesis , Receptors, Chemokine/immunology , T-Lymphocytes, Regulatory/cytology , T-Lymphocytes, Regulatory/metabolism , Thymus Gland/cytology , Thymus Gland/metabolismABSTRACT
The adoptive transfer of donor CD4+CD25+ regulatory T cells has been shown to protect from lethal graft-versus-host disease after allogeneic bone marrow transplantation in murine disease models. Efficient isolation strategies that comply with good manufacturing practice (GMP) guidelines are prerequisites for the clinical application of human CD4+CD25+ regulatory T cells. Here we describe the isolation of CD4+CD25+ T cells with regulatory function from standard leukapheresis products by using a 2-step magnetic cell-separation protocol performed under GMP conditions. The generated cell products contained on average 49.5% CD4+CD25high T cells that phenotypically and functionally represented natural CD4+CD25+ regulatory T cells and showed a suppressive activity comparable to that of CD4+CD25+ regulatory T-cell preparations purified by non-GMP-approved fluorescence-activated cell sorting.
Subject(s)
Adoptive Transfer , Graft vs Host Disease/therapy , Leukapheresis , T-Lymphocytes, Regulatory/cytology , Animals , Bone Marrow Transplantation , Clinical Trials as Topic , Disease Models, Animal , Flow Cytometry/methods , Flow Cytometry/standards , Graft vs Host Disease/etiology , Guidelines as Topic/standards , Humans , Leukapheresis/methods , Leukapheresis/standards , Mice , T-Lymphocytes, Regulatory/transplantation , Transplantation, HomologousABSTRACT
Graft-versus-host disease is a major complication after allogeneic bone marrow transplantation (BMT) caused by donor T cells. Immunosuppression mediated by CD4(+)CD25(+) regulatory T cells has been shown to ameliorate such pathogenic immune responses in animal models. Here, we summarize recent findings from experimental and clinical studies and propose a model for peripheral tolerance induction after BMT.
